These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39167797)

  • 41. Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
    Liu N; Yang X; Gao C; Wang J; Zeng Y; Zhang L; Yin Q; Zhang T; Zhou H; Li K; Du J; Zhou S; Zhao X; Zhu H; Yang Z; Liu Z
    J Nucl Med; 2024 May; 65(5):728-734. PubMed ID: 38514084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
    Wu Y; Yi M; Niu M; Mei Q; Wu K
    Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.
    Ghorbaninezhad F; Asadzadeh Z; Masoumi J; Mokhtarzadeh A; Kazemi T; Aghebati-Maleki L; Shotorbani SS; Shadbad MA; Baghbanzadeh A; Hemmat N; Bakhshivand M; Baradaran B
    Life Sci; 2022 May; 297():120466. PubMed ID: 35271882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [
    Zhang Z; Tan J; Yu Z; Liu C; Wang J; Wu D; Bai X
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 May; 43(5):667-679. PubMed ID: 37313807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers.
    He R; Lu J; Feng J; Lu Z; Shen K; Xu K; Luo H; Yang G; Chi H; Huang S
    Front Immunol; 2024; 15():1435187. PubMed ID: 39026661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier.
    Lu Z; Chen H; Jiao X; Zhou W; Han W; Li S; Liu C; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li Y; Li J; Li Y; Brock M; Zhang H; Shen L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32792359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
    Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
    Front Immunol; 2022; 13():900273. PubMed ID: 36159856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel post-translational modifications of protein by metabolites with immune responses and immune-related molecules in cancer immunotherapy.
    Chen L; Huang L; Gu Y; Li C; Sun P; Xiang Y
    Int J Biol Macromol; 2024 Oct; 277(Pt 1):133883. PubMed ID: 39033895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.